Canada's National Advisory Committee on immunization: Adaptations and challenges during the COVID-19 pandemic.

(COVID-19 pandemic) (NITAG) (National Advisory Committee on Immunization) (National Immunization Technical Advisory Group) (Vaccine)

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
20 10 2023
Historique:
received: 13 11 2022
revised: 04 06 2023
accepted: 18 08 2023
medline: 23 10 2023
pubmed: 2 9 2023
entrez: 1 9 2023
Statut: ppublish

Résumé

The COVID-19 pandemic has challenged traditional vaccine guidance infrastructure and frameworks, and added urgency and complexity to the operation of National Immunization Technical Advisory Groups (NITAGs). Canada's National Advisory Committee on Immunization (NACI) provides immunization guidance to the Public Health Agency of Canada (PHAC) who publicly shares expert and evidence-informed guidance with Canadian provinces and territories. Throughout the pandemic, NACI and PHAC implemented many adaptations to meet urgent needs for pandemic vaccine guidance. In this paper, we describe: structural adaptations in response to the accelerated pace and amount of work required to issue recommendations that were timed around product authorizations and dynamic epidemiology; technical adaptations in response to rapidly evolving evidence of variable quality which required close monitoring, and which promoted reliance on basic vaccine principles due to incomplete direct evidence; the need to provide nimble advice (e.g., off-label recommendations, preferential recommendations); communications adaptations (e.g. identify sustainable spokespeople for the committee, receive stakeholder feedback, and ensure urgent nuanced advice was communicated to a diverse audience); and research adaptations focussing on solutions to constrained supply (e.g. prioritisation, extended intervals, and heterologous schedules). The early pandemic vaccine experience has created a roadmap of lessons and adaptations that should be leveraged in future pandemic vaccine programs, and has highlighted the essential role of NITAGs to complement regulatory structures during pandemics to ensure timely, impactful, and evidence-informed public health vaccine guidance.

Identifiants

pubmed: 37658002
pii: S0264-410X(23)00991-X
doi: 10.1016/j.vaccine.2023.08.048
pii:
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6538-6547

Informations de copyright

Crown Copyright © 2023. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Matthew Tunis, Shainoor Ismail, Marina Salvadori, Bryna Warshawsky, Kelsey Young, Christine Mauviel, and Erin Henry are employed by the Public Health Agency of Canada. Shelley Deeks and Robyn Harrison are the current Chair and Vice Chair of NACI, but not compensated for these roles. Caroline Quach was a previous Chair of NACI during the COVID-19 pandemic, but not compensated for this role. All authors contributed to the conception of the study, drafting the article, and approved the submitted version.

Auteurs

Matthew Tunis (M)

Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Ontario, Canada. Electronic address: matthew.tunis@phac-aspc.gc.ca.

Shelley Deeks (S)

Department of Health and Wellness, Nova Scotia, Canada; Community Health and Epidemiology, Dalhousie University, Nova Scotia, Canada.

Robyn Harrison (R)

Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Alberta Health Services, Edmonton, Alberta, Canada.

Caroline Quach (C)

Department of Microbiology, Infectious Diseases and Immunology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada; Infection Prevention and Control, Department of Clinical Laboratory Medicine, CHU Sainte-Justine, Montreal, Quebec, Canada.

Shainoor Ismail (S)

Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Ontario, Canada; Metro City Medical Clinic, Edmonton, Alberta, Canada.

Marina Salvadori (M)

Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Ontario, Canada.

Bryna Warshawsky (B)

Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.

Kelsey Young (K)

Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Ontario, Canada.

Christine Mauviel (C)

Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Ontario, Canada.

Erin Henry (E)

Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH